Hexagon Bio Raises $62M Series C+ Led by The Column Group for ADC Payload Discovery

Hexagon Bio, a Menlo Park, California-based biopharmaceutical company, has raised a $62 million Series C+ round. The Column Group led the financing, with participation from Nextech Invest, Canada Pension Plan Investment Board, 8VC, and Deviation Capital. The round was dated October 23, 2026.

What the Company Does

Hexagon Bio discovers next-generation antibody-drug conjugate (ADC) payload mechanisms by mining cytotoxic small molecules from microbial genomes. Its proprietary platform combines DNA sequencing, data science, and synthetic biology to identify natural-product payloads that are orthogonal to the widely used topoisomerase and tubulin inhibitor classes.

Pipeline

The company's lead program, HEX-360, is a HER2-targeting ADC with a novel translation-inhibitor payload. HEX-360 is moving toward first-in-human studies. Hexagon Bio's broader pipeline is aimed at solid tumors and hematological malignancies.

Why It Matters for Acquirers

ADC dealmaking has concentrated heavily around a small number of validated payload classes, and payload diversification is one of the field's most closely watched problems. Hexagon Bio's thesis is that microbial genomes contain cytotoxic small molecules capable of bypassing resistance and toxicity limitations associated with topoisomerase and tubulin inhibitors.

The company's strategic profile rests on several elements:

• Platform differentiation: a discovery engine spanning sequencing, data science, and synthetic biology applied to natural-product payload discovery.
• A clinical-stage-adjacent lead asset: HEX-360 is a HER2-targeting ADC advancing toward first-in-human studies, giving the platform a concrete test case.
• Payload novelty: a translation-inhibitor mechanism distinct from the dominant ADC payload classes.
• Indication breadth: a pipeline spanning solid tumors and hematological malignancies.

For large pharma and ADC-focused buyers, Hexagon Bio offers both a payload discovery platform and a lead program approaching the clinic. The Series C+ structure suggests an extension of prior institutional support rather than a first-time financing, and the investor group includes crossover and sovereign participation alongside specialist life science funds.

Round Details

• Company: Hexagon Bio
• Headquarters: Menlo Park, California
• Round type: Series C+
• Amount: $62 million
• Currency: USD
• Date: October 23, 2026
• Lead investor: The Column Group
• Participating investors: Nextech Invest, Canada Pension Plan Investment Board, 8VC, Deviation Capital

What to Watch

Key milestones include HEX-360's progression toward first-in-human studies and any further pipeline programs emerging from the microbial genome mining platform. Evidence that novel payload classes translate into differentiated clinical profiles would be the central value driver for both investors and potential acquirers.